Edmond DE Rothschild Holding S.A. Purchases Shares of 4,503,300 DENTSPLY SIRONA Inc. $XRAY

Edmond DE Rothschild Holding S.A. purchased a new stake in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) during the second quarter, according to its most recent 13F filing with the SEC. The firm purchased 4,503,300 shares of the medical instruments supplier’s stock, valued at approximately $47,780,000. Edmond DE Rothschild Holding S.A. owned approximately 2.26% of DENTSPLY SIRONA as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently modified their holdings of XRAY. First Eagle Investment Management LLC grew its holdings in DENTSPLY SIRONA by 3.2% in the fourth quarter. First Eagle Investment Management LLC now owns 14,640,555 shares of the medical instruments supplier’s stock worth $167,342,000 after purchasing an additional 458,744 shares during the last quarter. UBS Group AG lifted its holdings in shares of DENTSPLY SIRONA by 63.7% during the 4th quarter. UBS Group AG now owns 1,701,980 shares of the medical instruments supplier’s stock valued at $19,454,000 after purchasing an additional 662,000 shares during the last quarter. Fiduciary Alliance LLC purchased a new stake in shares of DENTSPLY SIRONA during the 1st quarter valued at $4,607,000. Cibc World Market Inc. boosted its position in shares of DENTSPLY SIRONA by 120.7% in the 4th quarter. Cibc World Market Inc. now owns 1,184,303 shares of the medical instruments supplier’s stock worth $13,537,000 after purchasing an additional 647,763 shares in the last quarter. Finally, Skylands Capital LLC purchased a new position in DENTSPLY SIRONA during the 4th quarter worth $1,079,000. Hedge funds and other institutional investors own 95.70% of the company’s stock.

Insider Activity at DENTSPLY SIRONA

In other DENTSPLY SIRONA news, Director Brian T. Gladden purchased 9,985 shares of the stock in a transaction on Monday, June 15th. The shares were bought at an average cost of $10.02 per share, with a total value of $100,049.70. Following the completion of the acquisition, the director owned 61,849 shares in the company, valued at $619,726.98. This trade represents a 19.25% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Michael J. Barber purchased 15,175 shares of the business’s stock in a transaction on Thursday, June 11th. The shares were bought at an average cost of $9.88 per share, for a total transaction of $149,929.00. Following the completion of the transaction, the director directly owned 55,943 shares in the company, valued at $552,716.84. This trade represents a 37.22% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders acquired 35,160 shares of company stock worth $351,179 over the last three months. Company insiders own 0.46% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on XRAY. UBS Group reduced their target price on DENTSPLY SIRONA from $18.00 to $17.00 and set a “buy” rating on the stock in a research report on Thursday, May 7th. Mizuho dropped their price target on DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 6th. Barrington Research set a $15.00 price objective on shares of DENTSPLY SIRONA in a report on Monday, August 10th. BMO Capital Markets reaffirmed a “market perform” rating and issued a $13.00 price objective on shares of DENTSPLY SIRONA in a research report on Friday, August 7th. Finally, Piper Sandler lifted their target price on shares of DENTSPLY SIRONA from $13.00 to $14.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 29th. Three analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, DENTSPLY SIRONA currently has a consensus rating of “Hold” and a consensus price target of $13.38.

DENTSPLY SIRONA Price Performance

Shares of NASDAQ XRAY opened at $11.03 on Thursday. DENTSPLY SIRONA Inc. has a 52 week low of $9.40 and a 52 week high of $14.86. The business’s 50 day moving average price is $11.99 and its 200 day moving average price is $11.82. The company has a quick ratio of 1.07, a current ratio of 1.63 and a debt-to-equity ratio of 1.48. The firm has a market cap of $2.20 billion, a P/E ratio of -4.01, a P/E/G ratio of 1.40 and a beta of 0.85.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $0.52 EPS for the quarter, beating the consensus estimate of $0.35 by $0.17. The business had revenue of $898.00 million during the quarter, compared to analysts’ expectations of $889.93 million. DENTSPLY SIRONA had a negative net margin of 14.99% and a positive return on equity of 20.84%. The business’s quarterly revenue was down 4.1% compared to the same quarter last year. During the same period in the previous year, the business posted $0.52 EPS. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. On average, sell-side analysts expect that DENTSPLY SIRONA Inc. will post 1.41 earnings per share for the current year.

DENTSPLY SIRONA Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.